Table 2.
Antimicrobial non-susceptibility among 198 invasive and non-invasive S. pneumoniae isolates of different serotypes.
| Serotype/serogroup(s) | No. (%) of nonsusceptible isolates |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PEN | AMP | CXM | CRO | ERY | CLI | TET | CHL | SXT | LEVO | |
| 3 | 4 (10.8) | 0 (0) | 0 (0) | 0 (0) | 3 (8.1) | 3 (8.1) | 3 (8.1) | 3 (8.1) | 0 (0) | 0 (0) |
| 19F | 25 (96.2) | 24 (92.3) | 21 (80.8) | 14 (53.8) | 26 (100.0) | 25 (96.2) | 26 (100.0) | 0 (0) | 24 (92.3) | 1 (3.8) |
| 19A | 19 (82.6) | 18 (78.3) | 18 (78.3) | 16 (69.6) | 16 (69.6) | 15 (65.2) | 15 (65.2) | 3 (13.0) | 18 (78.3) | 0 (0) |
| 6A | 5 (41.7) | 1 (8.3) | 1 (8.3) | 1 (8.3) | 7 (58.3) | 2 (16.7) | 1 (8.3) | 5 (41.7) | 7 (58.3) | 0 (0) |
| 15A/B/C | 6 (54.5) | 1 (9.1) | 0 (0) | 0 (0) | 5 (45.4) | 3 (27.3) | 5 (45.4) | 0 (0) | 5 (45.4) | 0 (0) |
| 6C | 7 (77.8) | 1 (11.1) | 1 (11.1) | 1 (11.1) | 6 (66.7) | 6 (66.7) | 7 (77.8) | 0 (0) | 2 (22.2) | 0 (0) |
| 23A | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 6 (85.7) | 6 (85.7) | 3 (42.9) | 4 (57.1) | 6 (85.7) | 0 (0) |
| Other PCV10 | 18 (52.9) | 12 (35.3) | 9 (26.5) | 6 (17.6) | 11 (32.3) | 8 (23.5) | 9 (26.5) | 6 (17.6) | 18 (52.9) | 1 (2.9) |
| Other Non-PCV10 | 5 (14.3) | 1 (2.9) | 0 (0) | 0 (0) | 4 (11.4) | 3 (8.6) | 5 (14.3) | 0 (0) | 7 (20.0) | 0 (0) |
| NT | 3 (75.0) | 2 (50.0) | 1 (25.0) | 1 (25.0) | 3 (75.0) | 1 (25.0) | 0 (0) | 0 (0) | 3 (75.0) | 0 (0) |
| Total No. (%) | 92 (46.5) | 60 (30.3) | 51 (25.8) | 39 (19.7) | 87 (43.9) | 72 (36.4) | 74 (37.4) | 21 (10.6) | 90 (45.4) | 2 (1.0) |
PEN, benzylpenicillin; AMP, ampicillin; CXM, cefuroxime iv; CRO, ceftriaxone; ERY, erythromycin; CLI, clindamycin; TET, tetracycline; CHL, chloramphenicol; SXT, trimethoprim-sulfamethoxazole; LEV, levofloxacin; NT, nontypable isolates.
The following non-susceptible MIC (μg/mL) breakpoints were used: benzylpenicillin ≥ 0.12; ampicillin/ceftriaxone/cefuroxime iv ≥ 1.0 μg/mL according to the EUCAST.15